Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03464305 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ASPIRIN Trial Belgium

Study acronym: ASPIRIN
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 31, 2026 to Dec 31, 2027
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 400 to confirmed 148
    • Study sites revised (29)
    v6
  2. Eligibility criteria expanded, about 32 words
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study sites revised (29)
    v5
  3. Site details revised at 6 of 29 sitesv4
  4. Study sites: 19 to 29v3
  5. Study sites: 5 to 19v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine whether acetylsalicylic acid is effective on the recurrence and survival of colon cancer patients.
Trial Details
NCT Number NCT03464305
Lead Sponsor University Hospital, Antwerp
Collaborators: Kom Op Tegen Kanker, Anticancerfund
Conditions
(from sponsor)		 Colon Cancer
Related terms Colonic Diseases, Colonic Neoplasms, Colorectal Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Site, Pathologic Processes, Recurrence
Enrollment 148 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov